UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 首要目标 贝伐单抗联合替莫唑胺/放疗治疗初诊胶质母细胞瘤的安全性和耐受性研究 为了评估新诊断的胶质母细胞瘤患者接受贝伐单抗/替莫唑胺/放射治疗后再接受贝伐单抗/替莫唑胺治疗2年或直到检测到病情进展的总体存活率。 次要目标 为了进一步研究贝伐单抗/替莫唑胺/放射治疗的安全性和耐受性，随后再使用贝伐单抗/替莫唑胺。 从冰冻和石蜡切片的肿瘤标本中分离出DNA、RNA和蛋白质，以供评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aim To investigate the safety and tolerability in newly-diagnosed patients with glioblastoma of the combination of bevacizumab with temozolomide/radiation To estimate the overall survival in subjects with newly-diagnosed glioblastoma treated with bevacizumab/temozolomide/radiation followed by bevacizumab/temozolomide for 2 years or until progression is detected. Secondary Aims To investigate further the safety and tolerability of bevacizumab/temozolomide/radiation followed by bevacizumab/temozolomide. To isolate DNA, RNA, and protein isolated from frozen and paraffinized archival tumor samples for evaluations.